Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma

Amzal, B., Fu, S., Meng, J. et al. (2 more authors) (2017) Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. PLoS ONE, 12 (9). e0184423. ISSN 1932-6203

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2017 Amzal et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Dates:
  • Published: 8 September 2017
  • Accepted: 23 August 2017
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 11 Oct 2017 09:56
Last Modified: 11 Oct 2017 10:02
Published Version: https://doi.org/10.1371/journal.pone.0184423
Status: Published
Publisher: Public Library of Science
Refereed: Yes
Identification Number: https://doi.org/10.1371/journal.pone.0184423
Related URLs:

Share / Export

Statistics